Background
Arterial stiffness has been used as an important predictor for atherosclerosis morbidity and mortality as well as aging [
1]. Accelerated arterial stiffness and vascular dysfunction have been observed in people with obesity, insulin resistance (IR), and metabolic syndrome (MetS) [
2,
3]. Low levels of serum adiponectin are also associated with MetS and are considered an independent marker of peripheral arterial stiffness in hypertensive patients [
4]. Adiponectin, also known as Acrp30, AdipoQ, and GBP28, is a 247-amino acid peptide that is secreted by adipocytes [
5] and aortic endothelial cells [
6] and circulates in large amounts (2–30 μg/mL) in plasma [
7]. It has multiple functions such as insulin-sensitization, atheroprotection and cancer prevention [
8,
9] by binding the adiponectin receptors (AdipoR1 and 2) on the tissues and cells [
10]. Low levels of adiponectin were positively associated with IR, endothelial dysfunction, and arterial stiffness in people with metabolic disorders such as obesity, MetS, cardiovascular disease (CVD), and type 2 diabetes (T2DM) [
8,
11]. However, recent studies reported that higher circulating adiponectin levels were found in heart failure patients [
12] and were positively correlated with carotid intima-media thickness (CIMT) [
13], thereby suggesting high adiponectin levels as a marker of CVD risk [
14]. The discrepancy between these results has not been fully resolved, but we speculate that it may be related to the adiponectin gene (
ADIPOQ,
ACDC, or
AMP1), a key regulator of adiponectin production and secretion [
15].
Among
ADIPOQ single nucleotide polymorphisms (SNPs), two SNPs, rs2241766 (+ 45T/G in exon 2) and rs1501299 (+ 276G/T in intron 2) have been studied mainly for their association with circulating adiponectin, obesity, IR, T2DM, and CVD risk [
15,
16]. The
ADIPOQ rs2241766 G allele has been associated with an increased incidence of T2DM [
15], and the
ADIPOQ rs1501299 T allele has been associated with decreases in IR and increases in circulating adiponectin [
17]. In addition, the haplotype that combines rs2241766 T/G and rs1501299 G/T is linked to the progress of MetS and reduction of plasma adiponectin levels [
16,
18]. In our previous study,
ADIPOQ rs1501299 G/T was more strongly associated than rs2241766 T/G with several components of MetS and CVD risk, including IR, circulating triglyceride, and LDL particle size in nonobese and nondiabetic Korean men [
18]. However, these associations between these two SNPs and IR are not observed in Europeans [
19,
20]. This suggests that the susceptibility to IR and CVD risk is heterogeneous among ethnic groups because of different effects of
ADIPOQ SNPs. However, it has not been investigated yet if the relationship between circulating adiponectin and arterial stiffness is associated with
ADIPOQ SNPs, particularly in Koreans.
Therefore, this study aimed to investigate if the relationship between adiponectin and arterial stiffness is associated with ADIPOQ rs1501299 G/T in non-diabetic Korean men, which may provide to be useful information for early prevention and management of atherosclerotic risk.
Methods
Study participants
Study participants (men) were recruited from the Health Service Center in the course of a routine checkup visit or by a newspaper announcement for health examinations (January 2016–March 2016). Participants did not have any history of diseases. Exclusion criteria were the following: (1) patients diagnosed for DM and stroke; (2) any diagnosis of vascular disease, cancer (clinically or by anamnesis), renal disease, liver disease, thyroid disease, and acute or chronic inflammatory disease; (3) orthopedic limitations; and (4) ~ 10% weight loss/gain over the previous 6 months. In addition, MetS was defined using a combination and modification of the NCEP-ATPIII guidelines, Asian-Pacific guidelines, and American Diabetes Association guidelines. The definition used requires at least three of the following components: waist circumference > 90 cm (men); triglyceride ≥ 150 mg/dL; high density lipoprotein cholesterol (HDL-cholesterol) < 40 mg/dL (men); systolic/diastolic blood pressure (BP) ≥ 130/≥ 85 mmHg; and fasting glucose ≥ 100 mg/dL (fasting glucose ≥ 126 mg/mL was considered diagnostic of DM). The study participants were interviewed regarding their smoking and drinking behavior and medications. None of the participants were taking any medications (antihypertensive, antidyslipidemic, antithrombotic, and antidiabetic drugs). All the participants were provided with detailed information of the study, and participants provided written informed consent. The study protocol was approved by the Institutional Review Board of Dong-A University and was carried out in accordance with the Helsinki Declaration. Finally, 301 individuals were included in the study.
Anthropometric parameters and blood collection
Height, body weight, and waist circumference were measured. Body mass index (BMI) was calculated as body weight divided by height in square meters (kg/m2). BP was obtained from seated individuals with an automatic BP monitor (HEM-7220, OMRON, Matsusaka, Japan) after a short rest. After an overnight fast, venous blood specimens were collected in EDTA-treated and untreated tubes. The tubes were immediately placed on ice until they arrived at the analytical laboratory (1–3 h). Subsequently, the blood specimens were separated into plasma or serum and stored at − 80 °C until analysis.
Serum lipid profile
Serum total cholesterol, triglyceride, and low-density lipoprotein (LDL) were measured using commercially available kits on a Hitachi 7150 Autoanalyzer (Hitachi Ltd., Tokyo, Japan). After precipitation of serum chylomicron, LDL, and very low-density lipoprotein with dextran sulfate and magnesium chloride, HDL-cholesterol left in the supernatant was measured by an enzymatic method.
Glucose, insulin, and HOMA-IR
Fasting glucose was measured by a glucose oxidase method (Glucose Analyzer Beckman Instruments, Irvine, CA, USA). Insulin was measured by radioimmuno-assays using commercial kits (Immuno Nucleo Corporation, Stillwater, MN, USA). IR was calculated with the homeostatic model assessment using the following equation: HOMA-IR = [fasting insulin (μIU/mL) × fasting glucose (mmol/L)]/22.5.
Plasma adiponectin
Plasma adiponectin concentrations were measured using an enzyme immunoassay (Human Adiponectin ELISA kit, B-Bridge International Inc., San Francisco, CA, USA). The resulting color reactions were measured using the iMark™ microplate absorbance reader (Bio-Rad Laboratories, Hercules, CA, USA).
Brachial-ankle pulse wave velocity
Brachial-ankle pulse wave velocity (baPWV) as a marker for arterial stiffness was measured using an automatic waveform analyzer (model VP-1000; Nippon Colin Ltd., Komaki, Japan). Subjects were examined in the supine position after 10 min of bed rest. Electrocardiogram electrodes were placed on both wrists, and a microphone for the phonogram was placed on the left edge of the sternum. Pneumonic cuffs were wrapped around both upper arms and ankles and connected to a plethysmographic sensor to determine the volume pulse waveform. Waveforms for the upper arm (brachial artery) and ankle (tibial artery) were stored for 10-s sample times with automatic gain analysis and quality adjustment. An oscillometric pressure sensor was attached to the cuffs to measure blood pressure at the four extremities. The baPWVs were recorded using a semiconductor pressure sensor (1200 Hz sample acquisition frequency) and calculated using the equation: (La − Lb)/ΔTba. The distance from the suprasternal notch to the elbow (Lb) or the ankle (La) were expressed by: Lb = [0.2195 × height of subject (cm)] − 2.0734, and La = [0.8129 × height of subject (cm)] + 12.328. Lb and La were defined as the distance from the aortic valve to the elbow and to the ankle, respectively. The time interval between arm and ankle distance (ΔTba) was defined as the pulse transit time between brachial and tibial arterial pressure waveforms. The average value of baPWV from both left and right sides was used in the analysis (correlation between the right and left baPWVs: r2 = 0.925, p < 0.0001).
The assessment of dietary intake and physical activity level
Information on each participant’s usual diet was obtained using both a 24-h recall and a semi-quantitative food frequency questionnaire, which was previously validated [
21]. We used the former to carry out analyses and the latter to check if the collected data was representative of the usual dietary pattern. All participants were given written and verbal instructions by a registered dietitian on completion of a 3-day (2 week days and 1 weekend) dietary record. Dietary energy values and nutrient content from the 3-day food records were calculated using the Computer Aided Nutritional Analysis Program (CAN-pro 4.0, Korean Nutrition Society, Seoul, Korea). Total energy expenditure (TEE) (kcal/day) was calculated from activity patterns (basal metabolic rate, 24 h-physical activity, and specific dynamic action of food).
Genotyping of ADIPOQ rs1501299 G/T polymorphism
Genotyping of
ADIPOQ rs1501299 G
/T was performed as described previously [
17,
18]. Genomic DNA was extracted from 5 mL whole blood using a commercially available DNA isolation kit (WIZARD Genomic DNA purification kit, Promega, Madison, WI, USA) according to the manufacturer’s protocol. The genotyping reaction was performed with SNP-IT assays using single primer extension technology (SNPstream 25K System, Orchid Biosystems, Princeton, NJ, USA). The DNA fragments were visualized by UV illumination using an Image Analyzer (AlphaImager 1220, Alpha Innotech, San Leandro, CA, USA). pUC19 DNA/MspI (HpaII) Marker (MBI Fermentas, Vilnius, Lithuania) was used as a control standard.
Statistical analysis
Statistical analyses were performed with Win SPSS ver. 24.0 (Statistical Package for the Social Science, SPSS Inc., Chicago, IL, USA). Differences in continuous variables among subgroups were tested with one-way analysis of variance followed by Bonferroni correction for multiple comparisons to reduce the rate of false positives. Non-continuous variables were tested with a χ2 test. A general linear model analysis (GLM, post hoc multiple comparison tests) followed by Bonferroni correction was also performed with adjustment for confounding factors [i.e. age, smoking status, alcohol consumption, TEE/total calorie intake (TEE/TCI), and BMI]. Pearson and partial correlation analyses were performed for the relationship among the variables. Stepwise linear regression analysis was also used to find the major determinants for arterial stiffness. The skewed variables were log-transformed for statistical analysis. For descriptive purposes, the mean values are presented using untransformed values. Results are expressed as mean ± standard error (S.E.) or percentages. A two-tailed value of p < 0.05 was considered statistically significant.
Discussion
The present study demonstrates that the relationship between circulating adiponectin and arterial stiffness expressed as baPWV is associated with the ADIPOQ rs1501299 G/T polymorphism in nondiabetic Korean men. Circulating adiponectin levels were negatively correlated with baPWV levels as well as HOMA-IR in rs1501299 T allele carriers, but these correlations were not significant in subjects with the GG genotype. Stepwise linear regression analysis revealed that systolic BP and circulating adiponectin were the main factors influencing baPWV levels in ADIPOQ rs1501299 T allele carriers. On the other hand, systolic BP, IR and age were the main contributors to increased baPWV levels in the GG subjects.
Previous studies have reported an inverse association between serum adiponectin and arterial stiffness in hypertensive patients [
4,
22,
23]. According to Tsioufis et al. [
23], decreased adiponectin levels lead to the elevation of mean baPWV levels in the presence of oxidative vascular injury. In a clinical study performed in 445 middle-aged Chinese participants, circulating adiponectin levels were independently and negatively associated with baPWV levels after adjustment for gender, age, BMI, number of MetS and kidney function [
22]. In addition, Jia et al. [
24] reported that increased arterial stiffness was directly associated with increased IR, leading to T2DM. These phenomena were also similarly observed in our subjects, but our current study additionally demonstrated that the relationships between circulating adiponectin, baPWV and IR are associated with the
ADIPOQ rs1501299 G/T polymorphism. Several studies demonstrated that adiponectin levels could be influenced by a variant of
ADIPOQ [
15‐
18]. The G variant of the
ADIPOQ rs2241766 T/G SNP is associated with decreased adiponectin levels and increased incidence of T2DM [
15]. However, the minor T allele at
ADIPOQ rs1501299 G/T polymorphism was associated with high levels of adiponectin and insulin sensitivity in non-diabetic men [
17]. In addition, the
ADIPOQ rs2241766-rs1501299 haplotype is linked to plasma adiponectin levels and the progress of MetS [
16,
18]: TT/TT subjects (T/T at both rs2241766 and rs1501299) showed significantly higher adiponectin levels and lower IR than did other carriers among nonobese and nondiabetic men [
18]. However, rs1501299 G/T rather than rs2241766 T/G was more strongly associated with components of MetS and CVD risk [
18]. On the other hand, subjects with the T allele at rs1501299 showed significantly lower HDL-cholesterol and higher baPWV, leading to an increase in arterial stiffness in essential hypertensive patients [
25]. The discrepancy among the study results may be due to the differences in study design (i.e. cross-sectional, case–control, intervention, prospective cohort, and meta-analysis studies, etc.), subject characteristics (i.e. age, sex, and ethnicity, etc.) and basic metabolic health status (i.e. super-healthy, metabolic disorders, patients with diseases, etc.) together with genetic properties. Our study subjects were all men aged between 31 and 50 years old without any history of disease or medication.
In fact, rs2241766 T/G located in exon 2 of
ADIPOQ codes for a silent mutation, Gly15Gly (GGT to GGG) [
26], which may explain why it does not strongly predispose nonobese and nondiabetic people to MetS, T2DM, or CVD compared with rs1501299 G/T [
18]. Although
ADIPOQ rs1501299 G/T is located in an intron which has had no known biological function, this SNP is associated with changes in circulating adiponectin levels, IR, and other CVD risk [
15‐
17,
27]. Moreover, the negative associations between circulating adiponectin and HOMA-IR or baPWV were apparent in rs1501299 T allele carriers among our study subjects. Although functional genomic study is needed to elucidate the T allele effect on the metabolic relationships, we speculate that the
ADIPOQ rs1501299 T variant alters RNA splicing or stability, leading to allele-specific differential adiponectin expression similar to the effects of intronic SNPs in the
Calpin10 and
collagen type I alpha 1 chain genes [
28,
29]. Another possible explanation is that rs1501299 is in linkage disequilibrium with other
ADIPOQ SNPs or other genes that have biological effects on adiponectin, IR or CVD risk [
25]. Furthermore, performing Mendelian randomization may affirm the effect of rs1501299 among
ADIPOQ and other related SNPs on the relationship between circulating adiponectin and arterial stiffness. However, only rs1501299 was investigated in this study. Based on our previous and current studies, we speculate that the T allele at
ADIPOQ rs1501299 G/T polymorphism may be an important genetic factor associated with increased adiponectin levels and decreased IR, thereby modulating arterial stiffness and lowering atherosclerotic risk in nondiabetic men.
Several studies have reported the correlation between baPWV and the onset of CVD or IR [
2,
3]. Hyperinsulinemia has been known to reduce the vasodilation capacity of insulin by attenuating nitric oxide production by endothelial cells [
30]. A recent study also suggested a clear relationship between IR and arterial stiffness in obese subjects [
3]. In our study, a significant relationship between baPWV and HOMA-IR was observed, specifically in subjects with the GG genotype, but not in the minor T allele carriers where instead a significant association between circulating adiponectin and baPWV was observed. These phenomena may be related to the possible insufficient production of adiponectin in subjects with rs1501299 GG genotype than those with T allele [
17,
18], that is, circulating adiponectin levels in the GG subjects might neither be sufficient to affect IR nor modulate arterial stiffness. Therefore, the significant association between baPWV and HOMA-IR observed in the GG subjects may be associated with other cardiometabolic risk factors besides adiponectin level. The specific mechanisms of the effect of
ADIPOQ rs1501299 on the associations between circulating adiponectin, and IR or arterial stiffness need to be further elucidated in a larger population.
Authors’ contributions
JS and OYK designed the experiments and wrote the manuscript. JS, SRY and OYK conducted the experiments and analyzed the data. OYK revised the manuscript and provided overall supervision for the project. All authors read and approved the final manuscript.